HR+ HER2-

Not all CDK4/6 inhibitors are the same. Learn how to compare Ibrance, Kisqali, and Verzenio based on overall survival rates, side effect management, and efficacy.

Learn why dose adjustments for CDK4/6 inhibitors are a proactive strategy for success. Get expert tips on managing diarrhea, fatigue, and neutropenia effectively.

The medical terms used in breast cancer treatment options can be confusing to understand, especially when you’re first navigating your diagnosis. To help you navigate the different treatment options, Dr. Pooja Advani, a breast medical oncologist at Mayo Clinic, provides a patient-friendly explanation of the major treatment types and breaks down how they work, who […]

For women with hormone receptor-positive (HR+) breast cancer or women who are at high risk for breast cancer, endocrine therapy is often recommended by their care team as part of their approach to treatment. Hot flashes and night sweats (also known as vasomotor symptoms) are common side effects of endocrine therapy, which can not only […]

Could my cancer still come back? You finish treatment. You count the years. You start to breathe again. And then, out of nowhere, the cancer shows up again. Not in your breast. Maybe not even in your chest area. But in your bones, your liver, your lungs. It’s called late recurrence, and for many people […]

Why does neck pain happen during breast cancer treatment? When you’re going through any kind of treatment for HR-positive/HER2-negative breast cancer, it’s possible you might experience neck pain. For many women with breast cancer, side effects like muscle pain, joint pain, and stiffness make it more difficult to get by on a daily basis. Managing […]

What tests are available for breast cancer patients? We were fortunate to recently host Dr. Sara Hurvitz, a medical oncologist and clinical research leader at Fred Hutch, as part of our “Ask the Expert” webinar series. Dr. Hurvitz led a deep dive into the important advancements in breast cancer testing that all patients should know. […]

What type of breast cancer is TRUQAP (capivasertib) for? TRUQAP is used with Fulvestrant to treat breast cancer with the following indications: hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic has an atypical PIK3CA, AKT1, or PTEN gene Breast cancer has worsened or returned within 12 months […]

CDK 4/6 inhibitors have received a lot of attention in the past few weeks for their role in treating early-stage breast cancer. On March 3, 2023, the FDA expanded the indication for use of Verzenio in a broader patient population, and on March 27, 2023 Novartis announced positive topline first results from its phase III […]

Endocrine therapy treatment for early-stage HR+ breast cancer is witnessing significant advances and moving away from the one-size-fits-all approach. Recent trials and genomic assays have paved the way for more tailored and targeted treatments that could improve outcomes for high-risk patients and deescalate treatment recommendations for low and intermediate-risk ones. Let’s delve into the new […]

If you were diagnosed with ER-positive, HER2-negative metastatic breast cancer and are now wondering if this new therapy is an option for your cancer, you are not alone! Outcomes4Me has a team of oncology nurse practitioners that would be happy to review your medical records and consult with you. If you have specific questions, please […]

What is endocrine therapy for breast cancer? Certain cancers—like breast cancer—are deeply affected by hormones. In order to stop cancer growth from occurring or to at least slow it down, there are treatments that exist that can alter or block the hormones. This type of treatment is most commonly referred to as hormone therapy or […]